Biovail Cardizem XL “approvable”
Executive Summary
Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...